Abstract
The progressive memory loss observed in Alzheimers disease (AD) is accompanied by an increase in the levels of amyloid-β peptide (Aβ) and a block of synaptic plasticity. Both synaptic plasticity and memory require changes in the expression of synaptic proteins such as the activity-regulated cytoskeleton-associated protein, Arc (also termed Arg3.1). Using a model of synaptic plasticity in which BDNF increases Arc expression in cultured cortical neurons, we have found that an oligomeric form of Aβ strongly inhibits the BDNF-induced increase of Arc expression. Given that Aβ oligomers are likely to be involved in the synaptic dysfunction and cognitive impairment observed in amyloid depositing mouse models, we hypothesize that inhibition of Arc induction by BDNF contributes to the synaptic and memory deficits at early stages of AD.
Keywords: Synaptic plasticity, Arg3.1, Arc, Alzheimer's disease, LTP, BDNE
Current Alzheimer Research
Title: Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons
Volume: 4 Issue: 5
Author(s): Valentine Echeverria, Diego E. Berman and Ottavio Arancio
Affiliation:
Keywords: Synaptic plasticity, Arg3.1, Arc, Alzheimer's disease, LTP, BDNE
Abstract: The progressive memory loss observed in Alzheimers disease (AD) is accompanied by an increase in the levels of amyloid-β peptide (Aβ) and a block of synaptic plasticity. Both synaptic plasticity and memory require changes in the expression of synaptic proteins such as the activity-regulated cytoskeleton-associated protein, Arc (also termed Arg3.1). Using a model of synaptic plasticity in which BDNF increases Arc expression in cultured cortical neurons, we have found that an oligomeric form of Aβ strongly inhibits the BDNF-induced increase of Arc expression. Given that Aβ oligomers are likely to be involved in the synaptic dysfunction and cognitive impairment observed in amyloid depositing mouse models, we hypothesize that inhibition of Arc induction by BDNF contributes to the synaptic and memory deficits at early stages of AD.
Export Options
About this article
Cite this article as:
Echeverria Valentine, Berman E. Diego and Arancio Ottavio, Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018190
DOI https://dx.doi.org/10.2174/156720507783018190 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets FMRI and Multiple Sclerosis
Current Medical Imaging Optimized Methods for In Vitro and In Vivo Anti-Inflammatory Assays and Its Applications in Herbal and Synthetic Drug Analysis
Mini-Reviews in Medicinal Chemistry Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Molecular Mechanisms, Emerging Etiological Insights and Models to Test Potential Therapeutic Interventions in Alzheimers Disease
Current Alzheimer Research Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research